On October 5, 2026, Eli Lilly and Gate Bioscience took their partnership to a new level. The latest agreement adds more drug targets and could push the total deal value past USD 870 million. That figure comes from a Reuters financial review.
Gate Bioscience, based in Brisbane, California, will lead the early discovery work. The focus is on oral small-molecule drugs that break down disease-causing proteins. The new deal brings in one confirmed target. Lilly can also pick a second. The upfront payment is still secret. Gate will get research funding, another payment if Lilly picks the second target, and a series of milestone payments for preclinical, clinical, and commercial progress. There are also tiered royalties on global net sales. Lilly gets exclusive worldwide rights to any drugs that come out of this work.
This is the second major agreement between Lilly and Gate Bioscience in about 15 months, following their initial collaboration announced in July 2025.
How molecular gates work and what’s at stake
Gate’s technology aims to block certain proteins from passing through the Sec61 secretory channel. This causes those proteins to break down. Gate says this approach could work for about 4,000 targets. These include proteins linked to immunology, neuroscience, and cardiometabolic disease. The company believes its method can reach proteins that have been tough to drug in the past. So far, Gate has not named specific candidates or shared data from its work with Lilly.
Under the new deal, Gate will handle early discovery using its Molecular Gate Discovery Platform. Lilly will take over for later preclinical and clinical development, manufacturing, and commercialization. This split of duties is the same as in their first agreement. Details are in the official company press release.
Gate will receive research funding, milestone payments for preclinical, clinical, and commercial achievements, as well as tiered royalties on global sales. Lilly obtains exclusive global rights to products developed for the selected targets.
Deal structure and industry context
The first agreement, signed in July 2025, was worth up to USD 856 million. This new expansion raises the stakes. It also shows Lilly’s growing trust in Gate’s platform. Gate came out of stealth with a USD 60 million Series A. Backers included Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Forbion and Lilly are also investors.
Gate’s method is part of a bigger trend in biotech. Companies are racing to find new ways to break down disease proteins. Other big deals include the recent partnership between Novartis and Abogen Biosciences. But Gate stands out. Its focus is the Sec61 channel and oral small molecules, not the usual protein degradation routes or delivery systems.
No specific molecular gate drug candidates or clinical results have been made public yet. The real impact of this alliance is still unknown. But Lilly’s move to expand and lock in global rights shows it is willing to take risks for big rewards in drug discovery. For Gate, this deal is a major step. It could turn its molecular gate idea into real treatments. The biotech world is watching. Can this approach finally reach targets that have been out of reach? Time will tell.
